Prana Biotechnology Limited (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 90   

Articles published

PRAN 1.42 0.00 (0.00%)
price chart
Stocks Underperform for the Week: Saia Inc , Prana Biotechnology Ltd
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has lost 6.67% during the past week and dropped 18.13% in the past 4 weeks.
What's Hurting These 3 Stocks? � Prana Biotechnology Limited (ADR) (NASDAQ ...
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) sank 70.49% early Monday after the Australian drug developer said its most advanced potential treatment failed to meet the main goal in a study of patients with Alzheimer's disease.
Related articles »  
Prana Biotechnology Limited (ADR) (PRAN) news: Prana Biotechnology - A ...
One company in particular, Prana Biotechnology (NASDAQ:PRAN), is well-positioned to address this market with their lead drug, and in a realistic but optimistic scenario, the share price could ducuple (increase by 10 times) by the end of the month.
Prana Biotechnology Limited (ADR) Short Interest Update
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) may face some pressure in the coming sessions. The short interest has registered a change of -6.86% for the month.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN): The Research Programs ...
Boston, MA, 04/09/2014 (usastockreport) - Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) announces issue of ordinary shares to carry out its business proceeds.
Related articles »  
Prana Biotechnology Limited (ADR) (PRAN) news: Prana Biotech -13% as ...
Prana is working under a different hypothesis. It, along with a growing number of scientists, now think that small beta-amyloid oligomers are the real culprits in Alzheimer's disease, because they have been found to float into synapses and short ...
Prana Biotechnology (PRAN) Stock Declines; Summer Street Not Impressed with ...  StreetInsider.com (subscription)
Related articles »  
Prana Biotechnology Limited (ADR) (PRAN) news: Prana: Right Drug, Wrong Dose
Prana Biotechnology Limited (NASDAQ:PRAN) is expected to release the results from its Phase 2b IMAGINE trial of PBT2 for the treatment of Alzheimer's disease within the coming month.
Underperforming Companies for the Week: EMCORE Corporation , Prana ...
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has lost 5.06% during the past week and dropped 19.79% in the past 4 weeks.
Prana Biotechnology Limited (ADR) (PRAN) news: Alzheimer's Dementia: Eli ...
In this article I will be analyzing the differences between Eli Lilly's (NYSE:LLY) Solanezumab and Prana Biotechnology's (NASDAQ:PRAN) PBT2 -- the new leading candidates in the treatment of Alzheimer's dementia and the implications for their ...
Why Prana Biotech's & Momenta Pharma's Stock Prices Fell Yesterday
Biotech stocks took a strong hit yesterday, with Prana Biotechnology Limited (ADR) (PRAN) falling over 70% and Momenta Pharmaceuticals, Inc. (MNTA) sliding over 16%.
Prana Biotechnology Limited shares crash on trial results  The Motley Fool
Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study  Bloomberg
Related articles »